14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AAPG vs VBIX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, VBIX (VBIX) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin), whereas VBIX carries 53.0/100 (HOLD) at $3.64 (N/M Forward P/E, -139.2% operating margin).
Growth vs. Quality Trade-Off: VBIX earns the overall head-to-head edge with a stronger Unified Composite Score (53.0/100 HOLD vs. AAPG 37.1/100 SELL) and -0.08β · 98% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8); meanwhile VBIX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 88.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs VBIX. Trailing 12-month operating profitability (AAPG -219.5% vs VBIX -139.2%) and valuation multiples (AAPG 8.4x vs VBIX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Internet Content & Information value chain with $40.4M market capitalization and -139.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AAPG vs VBIX Key Questions & Quantitative Answers
As of Nov 20, 2026, VBIX (VBIX) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin), whereas VBIX carries 53.0/100 (HOLD) at $3.64 (N/M Forward P/E, -139.2% operating margin). Growth vs. Quality Trade-Off: VBIX earns the overall head-to-head edge with a stronger Unified Composite Score (53.0/100 HOLD vs. AAPG 37.1/100 SELL) and -0.08β · 98% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8); meanwhile VBIX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 88.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AAPG leads the Growth & Scale pillar: AAPG posts +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin), compared with VBIX at -56.7% YoY revenue growth and +0.0% YoY earnings growth on $1.6M TTM revenue (81.1% gross margin, -139.2% operating margin). On trailing 12-month operating scale, AAPG generates $643M in USD-normalized revenue versus $1.6M for VBIX. In operating R&D and SG&A reinvestment, AAPG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VBIX.
AAPG screens cheaper on headline valuation multiples. AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin), whereas VBIX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAPG (-236.6% ROE) versus VBIX (-214.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk). By comparison, VBIX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.